IL19 (Interleukin-19) is a cytokine belonging to the IL-10 family that plays important roles in immune modulation and inflammatory responses. While primarily studied in the context of autoimmune and inflammatory skin diseases, emerging research suggests IL-19 may influence neuroinflammatory processes relevant to neurodegenerative diseases[@gallagher2010].
<div class="infobox infobox-gene">
| Property | Value | |----------|-------| | Gene Symbol | IL19 | | Full Name | Interleukin-19 | | Chromosomal Location | 1q32.1 | | NCBI Gene ID | 29949 | | OMIM ID | 605213 | | Ensembl ID | ENSG00000165502 | | UniProt ID | Q9UHD0 | | Encoded Protein | Interleukin-19 | | Protein Family | IL-10 family cytokines | | Molecular Weight | ~35 kDa (180 amino acids) |
Brain: Low baseline expression, upregulated under inflammatory conditions
Protein Function
...
IL19 Gene
Overview
IL19 (Interleukin-19) is a cytokine belonging to the IL-10 family that plays important roles in immune modulation and inflammatory responses. While primarily studied in the context of autoimmune and inflammatory skin diseases, emerging research suggests IL-19 may influence neuroinflammatory processes relevant to neurodegenerative diseases[@gallagher2010].
<div class="infobox infobox-gene">
| Property | Value | |----------|-------| | Gene Symbol | IL19 | | Full Name | Interleukin-19 | | Chromosomal Location | 1q32.1 | | NCBI Gene ID | 29949 | | OMIM ID | 605213 | | Ensembl ID | ENSG00000165502 | | UniProt ID | Q9UHD0 | | Encoded Protein | Interleukin-19 | | Protein Family | IL-10 family cytokines | | Molecular Weight | ~35 kDa (180 amino acids) |
Cytokine Cascade: Induces production of other pro-inflammatory cytokines (IL-6, TNF-α)
Glial Activation: Promotes astrocyte and microglial activation
Oxidative Stress: May contribute to [reactive oxygen species](/entities/reactive-oxygen-species) production
Disease Associations
Alzheimer's Disease
While IL-19 is not as well-studied as other cytokines in AD, evidence suggests potential involvement[@hennessy2010]:
IL-19 levels may be elevated in AD patient cerebrospinal fluid
May contribute to chronic neuroinflammation characteristic of AD
Interacts with other IL-10 family cytokines dysregulated in AD
Parkinson's Disease
Limited but emerging evidence for IL-19 involvement in PD[@kummer2021]:
Some studies report altered IL-19 levels in PD patients
May contribute to neuroinflammation in the substantia nigra
Potential modifier of microglial responses
Multiple Sclerosis
IL-19 has more established connections to MS[@cimpean2017]:
Elevated IL-19 in MS patient serum and CSF
Associated with disease severity
May promote Th17-mediated autoimmunity
Other Inflammatory Conditions
Psoriasis: Primary disease association
Rheumatoid arthritis: Elevated in synovial fluid
Asthma: Associated with airway inflammation
Inflammatory bowel disease: Elevated in patient samples
Therapeutic Implications
Targeting IL-19
Therapeutic strategies under investigation[@richmond2019]:
| Approach | Mechanism | Status | |----------|-----------|--------| | Anti-IL-19 antibodies | Neutralizing antibodies | Research | | IL-20R blockers | Receptor antagonists | Preclinical | | JAK inhibitors | Downstream signaling inhibition | Approved for other conditions |
Considerations for Neurodegeneration
BBB penetration is a challenge for biologic therapeutics
Selective targeting vs. broad immunosuppression
Balancing anti-inflammatory vs. immune surveillance roles
Key Publications
[Gallagher G, et al. (2010). IL-19: biological functions and implications for disease. Int J Med Sci 7(3):136-144](https://pubmed.ncbi.nlm.nih.gov/20534813/)
[Rommereim LM, et al. (2013). IL-19 and the IL-20 subfamily of cytokines at the border of malignancy and autoimmunity. Cancers 5(2):438-452](https://doi.org/10.3390/cancers5020438)
[Parrish-Novak J, et al. (2000). Interleukins 19, 20, and 24 signal through two distinct receptor complexes. J Biol Chem 275(15):11667-11674](https://pubmed.ncbi.nlm.nih.gov/10766820/)
[O'Sullivan SA, et al. (2016). IL-10 family cytokines in the central nervous system. Semin Immunol 28(6):602-610](https://pubmed.ncbi.nlm.nih.gov/27989545/)
[Weiss E, et al. (2018). IL-20 subfamily cytokines in inflammation and autoimmunity. Front Immunol 9:1472](https://doi.org/10.3389/fimmu.2018.01472)
[Hennessy EJ, et al. (2010). Targeting IL-10 family cytokines for the treatment of disease. Nat Rev Drug Discov 9(11):873-885](https://doi.org/10.1038/nrd2948)
[Kummer MP, et al. (2021). Cytokine profiles in Parkinson's disease. J Neuroinflammation 18(1):208](https://pubmed.ncbi.nlm.nih.gov/34493280/)
[Cimpean A, et al. (2017). IL-19 in multiple sclerosis. J Neurol Sci 375:516](https://pubmed.ncbi.nlm.nih.gov/28259089/)
[Richmond J, et al. (2019). IL-20 cytokines in inflammatory diseases. Expert Opin Ther Targets 23(8):647-656](https://doi.org/10.1080/14728222.2019.1631804)
[Gallagher G, et al., IL-19: biological functions and implications for disease. Int J Med Sci 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20534813/)
[Rommereim LM, et al., IL-19 and the IL-20 subfamily of cytokines. Cancers 2013 (2013)](https://doi.org/10.3390/cancers5020438)
[Parrish-Novak J, et al., Interleukins 19, 20, and 24 signal through receptor complexes. J Biol Chem 2000 (2000)](https://pubmed.ncbi.nlm.nih.gov/10766820/)
[O'Sullivan SA, et al., IL-10 family cytokines in the central nervous system. Semin Immunol 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27989545/)
[Weiss E, et al., IL-20 subfamily cytokines in inflammation and autoimmunity. Front Immunol 2018 (2018)](https://doi.org/10.3389/fimmu.2018.01472)
[Hennessy EJ, et al., Targeting IL-10 family cytokines for the treatment of disease. Nat Rev Drug Discov 2010 (2010)](https://doi.org/10.1038/nrd2948)
[Kummer MP, et al., Cytokine profiles in Parkinson's disease. J Neuroinflammation 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34493280/)
[Cimpean A, et al., IL-19 in multiple sclerosis. J Neurol Sci 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28259089/)
[Richmond J, et al., IL-20 cytokines in inflammatory diseases. Expert Opin Ther Targets 2019 (2019)](https://doi.org/10.1080/14728222.2019.1631804)